• Explore /
  • Poster
  • / The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).

The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Abstract Poster

Authors

Maryam Lustberg

Maryam B. Lustberg

Ohio State University Comprehensive Cancer Center, Division of Medical Oncology, Columbus, OH

Maryam B. Lustberg , Per Pfeiffer , Camilla Qvortrup , Kei Muro , Marie Helene Bengtson , Malin Nittve , Christian Sonesson , Fumiko Nagahama , Yusuke Sonehara , Carl Stefan Carlsson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03654729

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS3616)

DOI

10.1200/JCO.2019.37.15_suppl.TPS3616

Abstract #

TPS3616

Poster Bd #

107b

Abstract Disclosures

Similar Posters

First Author: Per Pfeiffer

First Author: In Gyu Hwang

First Author: Patricio Eduardo Yanez

First Author: Jennifer Leigh Lund